The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates

The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates

Several COVID-19 platforms have been licensed across the world thus far, but vaccine platform research that can lead to effective antigen delivery is still ongoing. Here, we constructed AdCLD-CoV19 that could modulate humoral immunity by harboring SARS-CoV-2 antigens onto a chimeric adenovirus 5/35...

Full description

Bibliographic Details
Main Authors: Seung-Phil Shin, Kwang-Soo Shin, Jeong-Mi Lee, In-Kyung Jung, Jimo Koo, Seung-Woo Lee, Seowoo Park, Jieun Shin, Myunghwan Park, Bongju Park, Hanseul Oh, Bon-Sang Koo, Jungjoo Hong, Choong-Min Ryu, Jae-Ouk Kim, Taegwon Oh, Chang-Yuil Kang
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Vaccines
Subjects:
SARS-CoV-2
variants
COVID-19 vaccine
chimeric adenovirus-vectored vaccine
GS linker
neutralizing activity
Online Access:https://www.mdpi.com/2076-393X/10/5/712

Internet

https://www.mdpi.com/2076-393X/10/5/712

Similar Items